These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 14559844

  • 1. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
    Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM.
    Cancer Res; 2003 Oct 01; 63(19):6506-15. PubMed ID: 14559844
    [Abstract] [Full Text] [Related]

  • 2. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

  • 3. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM.
    Cancer Res; 2000 Sep 01; 60(17):4946-52. PubMed ID: 10987311
    [Abstract] [Full Text] [Related]

  • 4. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.
    Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M.
    J Immunol; 2003 Feb 01; 170(3):1490-7. PubMed ID: 12538712
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.
    Clin Cancer Res; 2006 Mar 15; 12(6):1921-7. PubMed ID: 16551878
    [Abstract] [Full Text] [Related]

  • 7. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K.
    Cancer Res; 2003 Sep 01; 63(17):5587-94. PubMed ID: 14500399
    [Abstract] [Full Text] [Related]

  • 8. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.
    J Immunol; 2005 Feb 01; 174(3):1751-9. PubMed ID: 15661941
    [Abstract] [Full Text] [Related]

  • 9. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D.
    J Immunol; 2000 Dec 15; 165(12):7253-61. PubMed ID: 11120859
    [Abstract] [Full Text] [Related]

  • 10. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S.
    J Immunol; 2004 Apr 15; 172(8):5095-102. PubMed ID: 15067093
    [Abstract] [Full Text] [Related]

  • 11. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.
    Clin Cancer Res; 2009 Jul 01; 15(13):4467-74. PubMed ID: 19531622
    [Abstract] [Full Text] [Related]

  • 12. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A.
    Cancer Immun; 2002 Sep 19; 2():12. PubMed ID: 12747757
    [Abstract] [Full Text] [Related]

  • 13. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E.
    Cancer Res; 2008 Feb 01; 68(3):901-8. PubMed ID: 18245493
    [Abstract] [Full Text] [Related]

  • 14. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H.
    Cancer Res; 2005 Nov 01; 65(21):10068-78. PubMed ID: 16267033
    [Abstract] [Full Text] [Related]

  • 15. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.
    J Immunol; 2010 Sep 15; 185(6):3445-55. PubMed ID: 20733200
    [Abstract] [Full Text] [Related]

  • 16. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E.
    Cancer Res; 2007 Jun 01; 67(11):5498-504. PubMed ID: 17545632
    [Abstract] [Full Text] [Related]

  • 17. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trümper L, Schroers R.
    Hum Immunol; 2007 Jul 01; 68(7):572-6. PubMed ID: 17584578
    [Abstract] [Full Text] [Related]

  • 18. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A.
    J Exp Med; 2000 Feb 21; 191(4):625-30. PubMed ID: 10684854
    [Abstract] [Full Text] [Related]

  • 19. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
    Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM.
    J Immunol; 2011 Jan 01; 186(1):312-22. PubMed ID: 21131422
    [Abstract] [Full Text] [Related]

  • 20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.